Immatics Biotechnologies Financials
| IMTXW Stock | USD 0.41 0.01 2.38% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.8704 |
|
|
The financial analysis of Immatics Biotechnologies is a critical element in measuring its lifeblood. Investors should not minimize Immatics Biotechnologies' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Immatics | Select Account or Indicator |
Understanding current and past Immatics Biotechnologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immatics Biotechnologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Immatics Biotechnologies' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Immatics Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of immatics biotechnologies GmbH. Check Immatics Biotechnologies' Beneish M Score to see the likelihood of Immatics Biotechnologies' management manipulating its earnings.
Immatics Biotechnologies Stock Summary
Immatics Biotechnologies is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | N44445117 G3165V125 |
| Location | Germany |
| Business Address | Paul-Ehrlich-Strasse 15, Tbingen, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.immatics.com |
| Phone | 49 7071 5397 0 |
| Currency | USD - US Dollar |
Immatics Biotechnologies Key Financial Ratios
| Return On Equity | -0.24 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.42) % | ||||
| Revenue | 54 M | ||||
| EBITDA | (88.93 M) |
Immatics Biotechnologies Key Income Statement Accounts
The reason investors look at the income statement is to determine what Immatics Biotechnologies' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 620K | 561K | 3.9M | 1.1M | 13.0M | 13.7M | |
| Interest Income | 790K | 850K | 5.7M | 9.4M | 13.8M | 14.5M | |
| Interest Expense | 170K | 289K | 1.7M | 8.3M | 831K | 789.5K | |
| Total Revenue | 18.4M | 31.3M | 34.8M | 172.8M | 54.0M | 57.8M | |
| Gross Profit | (21.6M) | (35.8M) | (52.8M) | 66.1M | (64.7M) | (61.4M) | |
| Operating Income | (33.0M) | (69.7M) | (86.3M) | 30.0M | (101.7M) | (96.6M) | |
| Ebit | (33.0M) | (68.6M) | (89.0M) | 43.2M | (96.2M) | (91.4M) | |
| Research Development | 40.1M | 67.1M | 87.6M | 106.8M | 118.7M | 83.3M | |
| Ebitda | (28.4M) | (64.4M) | (83.6M) | 50.0M | (88.9M) | (84.5M) | |
| Income Before Tax | (32.5M) | (229.6M) | (93.3M) | 42.0M | (97.0M) | (101.8M) | |
| Net Income | (31.7M) | (229.3M) | (95.1M) | 37.5M | (97.0M) | (101.8M) | |
| Income Tax Expense | (746K) | (268K) | 1.7M | 4.6M | 831K | 573.8K |
Immatics Biotechnologies Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (5.1M) | (15.9M) | 7.5M | (209.8M) | (31.4M) | (33.0M) | |
| Change In Cash | 64.0M | 104.2M | (74.5M) | 15.5M | 70.0M | 73.5M | |
| Free Cash Flow | 68.7M | (93.1M) | (87.4M) | 93.9M | (12.7M) | (12.1M) | |
| Depreciation | 3.9M | 4.4M | 5.3M | 7.0M | 7.2M | 5.5M | |
| Other Non Cash Items | 1.2M | 145.9M | 433K | (8.7M) | 5.7M | 5.4M | |
| Capital Expenditures | 2.2M | 7.5M | 5.7M | 6.2M | 31.0M | 32.5M | |
| Net Income | (32.5M) | (229.6M) | (93.3M) | 37.5M | (97.0M) | (101.8M) | |
| End Period Cash Flow | 103.4M | 207.5M | 133.0M | 148.5M | 218.5M | 155.9M |
Immatics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immatics Biotechnologies's current stock value. Our valuation model uses many indicators to compare Immatics Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immatics Biotechnologies competition to find correlations between indicators driving Immatics Biotechnologies's intrinsic value. More Info.immatics biotechnologies GmbH is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . At this time, Immatics Biotechnologies' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Immatics Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Immatics Biotechnologies Systematic Risk
Immatics Biotechnologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immatics Biotechnologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Immatics Biotechnologies correlated with the market. If Beta is less than 0 Immatics Biotechnologies generally moves in the opposite direction as compared to the market. If Immatics Biotechnologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immatics Biotechnologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immatics Biotechnologies is generally in the same direction as the market. If Beta > 1 Immatics Biotechnologies moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Immatics Biotechnologies is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Immatics has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Immatics Biotechnologies' financials are consistent with your investment objective using the following steps:- Review Immatics Biotechnologies' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Immatics Biotechnologies' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Immatics Biotechnologies' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Immatics Biotechnologies' stock is overvalued or undervalued.
Today, most investors in Immatics Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immatics Biotechnologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Immatics Biotechnologies growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Immatics Biotechnologies November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Immatics Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of immatics biotechnologies GmbH. We use our internally-developed statistical techniques to arrive at the intrinsic value of immatics biotechnologies GmbH based on widely used predictive technical indicators. In general, we focus on analyzing Immatics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immatics Biotechnologies's daily price indicators and compare them against related drivers.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 66.99 | |||
| Value At Risk | (14.74) | |||
| Potential Upside | 12.15 |
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.